We evaluated the impact of clopidogrel 150 mg/d in patients with chronic kidney disease (CKD) having clopidogrel resistance (CR) after percutaneous coronary intervention (PCI); 1076 consecutive patients with coronary artery disease (CAD) having CKD were enrolled. Maximal platelet aggregation (MPA) was assessed before, 24 hours, and 30 days after a 300-mg loading dose of clopidogrel prior to PCI. After PCI, 370 patients with CR were randomized to receive clopidogrel 75 mg/d (n = 184) or 150 mg/d (n = 186) for 30 days. Stent thrombosis (ST), major adverse cardiac events (MACEs), and bleeding were analyzed after 1 month. Patients in the 150 mg group had significant lower rates of ST and MACE. There was no significant difference in major or minor bleeding. Patients in the 150 mg group had lower MPA and greater inhibition of platelet aggregation. One-month administration of 150 mg/d of clopidogrel decreases the rate of ST and MACE without increasing bleeding in patients with CKD having CR after PCI.
AndersonJLAdamsCDAntmanEM. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction). J Am Coll Cardiol. 2007;50(7):e1–e157.
2.
SteinhublSRBergerPBMannJTIII. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–2420.
3.
AngiolilloDJFernandez-OrtizABernardoE. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516.
4.
LindenMDTranHWoodsRTonkinA. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost. 2012;38(2):200–212.
5.
GurbelPABlidenKPHiattBLO’ConnorCM. Clopidogrel for coronary stenting: response variability, drug resistance and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–2913.
6.
MorelOEI GhannudiSJeselL. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57(4):399–408.
7.
BuonamiciPMarcucciRMiglioriniA. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007;49(24):2312–2317.
8.
GaoWZhangQGeHGuoYZhouZ. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology. 2013;64(7):554–558.
9.
BasraSSTsaiPLakkisNM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. J Am Coll Cardiol. 2011;58(22):2263–2269.
10.
MullerCCaillardSJeselL. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis. 2012;59(6):777–785.
11.
MehranRNikolskyELanskyAJ. Impact of chronic kidney disease on early(30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY(Acute Catheterization and Urgent Intervention Triage strategY) substudy. JACC Cardiovasc Interv. 2009;2(8):748–757.
12.
LatifFKleimanNSCohenDJ. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2009;2(1):37–45.
13.
MaruyamaHFukuokaTDeguchiI. Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients. Intern Med. 2014;53(3):215–219.
14.
PattiGGriecoDDicuonzoGPasceriVNuscaADi SciascioG. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg(antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. J Am Coll Cardiol. 2011;57(7):771–778.
15.
AngiolilloDJShoemakerSBDesaiB. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy In Diabetes Mellitus(OPTIMUS) study. Circulation. 2007;115(6):708–716.
16.
AradiDRidegOVorobcsukA. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. Eur J Clin Invest. 2012;42(4):384–392.
17.
CharytanDKuntzRE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70(11):2021–2030.
18.
DasguptaASteinhublSRBhattDL; CHARISMA Investigators Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial). Am J Cardiol. 2009;103(10):1359–1363.
19.
StegPGHuberKAndreottiF. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854–1864.
20.
SantopintoJJFoxKAGoldbergRJ; GRACE Investigators. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003;89(9):1003–1008.
21.
BestPJSteinhublSRBergerPB; CREDO Investigators. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687–693.
22.
LeveyASBoschJPLewisJBGreeneTRogersNRothD. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461–470.
23.
MauriLHsiehWHMassaroJMHoKKD’AgostinoRCutlipDE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356(10):1020–1029.
24.
AntmanEMLouwerenburgHWBaarsHF. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis In Myocardial Infarction(TIMI) 23 trial. Circulation. 2002;105(14):1642–1649.
25.
LeonciniMTosoAMaioliM. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: the ACHIDO (Atorvastatin and Clopidogrel High DOse in stable patients with residual high platelet activity) study. JACC Cardiovasc Interv. 2013;6(2):169–179.
26.
ParkSHKimWParkCSKangWYHwangSHKimW. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104(9):1292–1295.
27.
AleilBJacqueminLDe PoliF. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02(Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv. 2008;1(6):631–638.
28.
CuissetTFrereCMoroPJ. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after acute coronary syndrome. Thromb Res. 2010;126(5):e400–e402.
29.
ThebaultJJKiefferGLoweGDNimmoWSCariouR. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost. 1999;25(suppl 2):9–14.
30.
WiviottSDBraunwaldEMcCabeCH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
31.
BonelloLCamoin-JauLArquesS. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51(14):1404–1411.
32.
TaubertDKastratiAHarlfingerS. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 2004;92(2):311–316.
33.
TrenkDHochholzerWFrommMF. Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20):1925–1934.
34.
PanicciaRAntonucciEGoriAm. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost. 2007;5(9):1839–1847.
35.
NakataTMiyaharaMNakataniK. Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation. Circ J. 2013;77(6):1436–1444.
36.
KarRMeenaAYadavBKYadavRKarSSSaxenaR. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Platelets. 2013;24(4):297–302.
